89bio, Inc. is a clinical-stage biopharmaceutical company operating in the field of biotechnology. Primarily focused in the United States, the company is engaged in developing innovative therapies to treat liver and cardio-metabolic diseases.
89bio operates in the healthcare industry. Through its bioscience technology, 89bio, Inc. develops a portfolio of products, including pegozafermin, which is engineered to treat diseases such as nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
Keep up-to-date on the latest share price changes by adding ETNB stock to your eToro watchlist.